Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Relapsed or Refractory CLL/SLL
NCT00193518Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2004
- Primary completion
- Apr 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate. Started Apr 2004; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00193518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193518.